New Light-Measuring tool tested in cancer surgery
NCT ID NCT03678350
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a light-measuring system used during photodynamic therapy (PDT) for people with malignant mesothelioma, non-small cell lung cancer, or other pleural cancers. Nine participants received the drug porfimer sodium, which becomes active when exposed to light, during surgery. The goal was to see if measuring the light dose could help doctors decide when to stop or continue treatment, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- porfimer sodium (Photofrin)
- What this could lead to
- If successful, this could help doctors deliver the right amount of light during photodynamic therapy, potentially improving treatment for pleural cancers.
- What could go wrong
- This is a very early, small Phase I trial with only 9 participants, focused on safety and light measurement, not on curing the disease. The approach may not work for everyone and carries risks from the light-activated drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill keep lung cancer from returning?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- Lab-Made immune protein takes on advanced cancers in first human test
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Experimental combo for lung cancer shows promise but study cut short